Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Veracyte stock

VCYT
US92337F1075
A1W7EA

Price

34.04
Today +/-
+0.24
Today %
+0.80 %
P

Veracyte stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Veracyte stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Veracyte stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Veracyte stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Veracyte's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Veracyte Stock Price History

DateVeracyte Price
9/30/202434.04 undefined
9/27/202433.77 undefined
9/26/202433.51 undefined
9/25/202433.35 undefined
9/24/202433.73 undefined
9/23/202434.26 undefined
9/20/202434.83 undefined
9/19/202435.25 undefined
9/18/202433.76 undefined
9/17/202434.32 undefined
9/16/202433.63 undefined
9/13/202432.92 undefined
9/12/202430.42 undefined
9/11/202430.32 undefined
9/10/202429.74 undefined
9/9/202429.08 undefined
9/6/202428.57 undefined
9/5/202429.77 undefined
9/4/202429.55 undefined
9/3/202430.29 undefined

Veracyte Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Veracyte, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Veracyte from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Veracyte’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Veracyte. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Veracyte’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Veracyte’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Veracyte’s growth potential.

Veracyte Revenue, EBIT and net profit per share

DateVeracyte RevenueVeracyte EBITVeracyte Net Income
2026e538.3 M undefined35.57 M undefined52.81 M undefined
2025e489.95 M undefined13.47 M undefined25.85 M undefined
2024e444.73 M undefined-9.88 M undefined9.74 M undefined
2023361.05 M undefined-17.45 M undefined-74.4 M undefined
2022296.5 M undefined-37.8 M undefined-36.6 M undefined
2021219.5 M undefined-59.8 M undefined-75.6 M undefined
2020117.5 M undefined-35.4 M undefined-34.9 M undefined
2019120.4 M undefined-15.1 M undefined-12.6 M undefined
201892 M undefined-22.2 M undefined-23 M undefined
201772 M undefined-26.5 M undefined-31 M undefined
201665.1 M undefined-28.8 M undefined-31.4 M undefined
201549.5 M undefined-33.5 M undefined-33.7 M undefined
201438.2 M undefined-29 M undefined-29.4 M undefined
201321.9 M undefined-23.2 M undefined-25.6 M undefined
201211.6 M undefined-18.9 M undefined-18.6 M undefined
20112.6 M undefined-15.3 M undefined-14.4 M undefined

Veracyte Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20112012201320142015201620172018201920202021202220232024e2025e2026e
211213849657292120117219296361444489538
-450.0090.9180.9528.9532.6510.7727.7830.43-2.5087.1835.1621.9622.9910.1410.02
-36.3642.8655.2657.1460.0059.7263.0469.1764.9666.2165.8868.70---
04921283943588376145195248000
-15-18-23-29-33-28-26-22-15-35-59-37-17-91335
-750.00-163.64-109.52-76.32-67.35-43.08-36.11-23.91-12.50-29.91-26.94-12.50-4.71-2.032.666.51
-14-18-25-29-33-31-31-23-12-34-75-36-7492552
-28.5738.8916.0013.79-6.06--25.81-47.83183.33120.59-52.00105.56-112.16177.78108.00
20.720.720.921.62628.833.93746.153.267.971.572.64000
----------------
Details

Keystats

ⓘ

Revenue and Growth

The Veracyte Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Veracyte is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
2011201220132014201520162017201820192020202120222023
                         
7.61471.23539.159.233.978159.3349.4173.2178.9216.45
0.20.61.13.13.58.812.713.219.318.541.54440.38
0000000000000
0.31.12.63.73.83.55.33.46.84.711.214.316.13
0.50.81.51.61.52.222.42.23.217.211.512.66
8.616.576.443.447.973.753.997187.6375.8243.1248.7285.62
1.72.434.210.311.59.78.917.716.831.130.930.86
0000000000000
0000000000000
0001615.214.113.1126559.9202.7174.988.59
0001.11.11.11.11.12.72.7707.9695.9702.98
0.20.20.30.30.80.70.91.7222.96.26.85
1.92.63.321.627.427.424.823.787.481.4944.6907.9829.29
0.010.020.080.070.080.10.080.120.280.461.191.161.11
                         
49.363.40000000.10.10.10.10.07
000.140.160.20.240.250.310.490.71.471.51.54
-41.4-60.1-85.6-115-148.7-180.1-211.1-234.1-246.7-281.6-357.2-393.7-468.12
0000000000-15.1-31.3-24.02
0000000000000
0.0100.060.040.050.060.040.080.240.421.11.081.04
0.61.95.37.45.12.43.92.52.33.112.411.912.94
1.347.67.98.79.18.29.215.113.343.141.843.53
03.12.51.90.900000.47.68.94.77
0000000000000
00000001.4001.100
1.9915.417.214.711.512.113.117.416.864.262.661.24
004.94.9525.525.223.90.70.80.60.40.1
0000.30000005.64.50.73
05.22.91.14.34.44.23.917.618.32113.78.73
05.27.86.39.329.929.427.818.319.127.218.69.56
1.914.223.223.52441.441.540.935.735.991.481.270.8
0.010.020.080.060.080.10.080.120.280.461.191.161.11
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Veracyte provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Veracyte's financial health and stability.

Assets

Veracyte's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Veracyte must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Veracyte after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Veracyte's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2011201220132014201520162017201820192020202120222023
-14-18-25-29-33-31-31-23-12-34-75-36-74
0011233347192527
0000000000-60-3
012400-6-50-404-16-4
1025912151219304861132
0000022100000
0000000000000
-13-7-19-27-26-27-23-13-3-9-31744
0-1-1-2-6-4-1-1-2-2-5-8-9
0-1-1-9-6-4-1-1-42-3-739-2915
000-60000-39-1-733-2025
0000000000000
004001900-2500-10
00660373325915220760579
1815770375205912720359632
18145000-100-3-9-3-6
0000000000000
4657-36420-254481190-176-1862
-13.8-8.63-20.49-29.65-33.14-32.19-25.68-15.39-5.99-12.55-37-1.0134.26
0000000000000

Veracyte stock margins

The Veracyte margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Veracyte. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Veracyte.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Veracyte's sales revenue. A higher gross margin percentage indicates that the Veracyte retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Veracyte's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Veracyte's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Veracyte's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Veracyte. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Veracyte's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Veracyte Margin History

Veracyte Gross marginVeracyte Profit marginVeracyte EBIT marginVeracyte Profit margin
2026e68.73 %6.61 %9.81 %
2025e68.73 %2.75 %5.28 %
2024e68.73 %-2.22 %2.19 %
202368.73 %-4.83 %-20.61 %
202265.77 %-12.75 %-12.34 %
202166.1 %-27.24 %-34.44 %
202064.68 %-30.13 %-29.7 %
201969.6 %-12.54 %-10.47 %
201864.02 %-24.13 %-25 %
201760.83 %-36.81 %-43.06 %
201660.83 %-44.24 %-48.23 %
201556.57 %-67.68 %-68.08 %
201456.54 %-75.92 %-76.96 %
201342.47 %-105.94 %-116.89 %
201234.48 %-162.93 %-160.34 %
2011-11.54 %-588.46 %-553.85 %

Veracyte Stock Sales Revenue, EBIT, Earnings per Share

The Veracyte earnings per share therefore indicates how much revenue Veracyte has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Veracyte earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Veracyte's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Veracyte’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Veracyte's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Veracyte Revenue, EBIT and net profit per share

DateVeracyte Sales per ShareVeracyte EBIT per shareVeracyte Earnings per Share
2026e7.01 undefined0 undefined0.69 undefined
2025e6.38 undefined0 undefined0.34 undefined
2024e5.79 undefined0 undefined0.13 undefined
20234.97 undefined-0.24 undefined-1.02 undefined
20224.15 undefined-0.53 undefined-0.51 undefined
20213.23 undefined-0.88 undefined-1.11 undefined
20202.21 undefined-0.67 undefined-0.66 undefined
20192.61 undefined-0.33 undefined-0.27 undefined
20182.49 undefined-0.6 undefined-0.62 undefined
20172.12 undefined-0.78 undefined-0.91 undefined
20162.26 undefined-1 undefined-1.09 undefined
20151.9 undefined-1.29 undefined-1.3 undefined
20141.77 undefined-1.34 undefined-1.36 undefined
20131.05 undefined-1.11 undefined-1.22 undefined
20120.56 undefined-0.91 undefined-0.9 undefined
20110.13 undefined-0.74 undefined-0.7 undefined

Veracyte business model

Veracyte Inc is a company that specializes in the development and marketing of diagnostic tests for a wide range of diseases and disorders. The company was founded in 2008 and is headquartered in South San Francisco, California. The history of Veracyte Inc begins with the vision to help patients with better diagnostic options. The company has used its expertise in gene expression technology to develop tests that facilitate the diagnosis of diseases and disorders in various areas, such as cancer, thyroid diseases, and lung diseases. Veracyte Inc's business model is based on selling diagnostic tests to healthcare facilities, hospitals, doctors, and other medical institutions. The tests are performed by specially trained professionals and can provide a precise diagnosis that helps doctors plan individualized treatment. Veracyte Inc is divided into different divisions to offer the best and most precise test for each area. The divisions include cancer diagnosis, thyroid diagnostics, lung diagnostics, and other areas of gene expression technology. In cancer diagnosis, Veracyte Inc offers tests for various types of cancer, such as breast cancer, thyroid cancer, and lung cancer. The tests use RNA sequencing to analyze the patient's genetic information and provide a more precise diagnosis. In thyroid diagnostics, Veracyte Inc offers tests for various thyroid diseases that are often difficult to diagnose. The tests help avoid unnecessary surgeries or medical interventions and enable patients to receive a more accurate diagnosis and treatment. In lung diagnostics, Veracyte Inc offers tests for pneumonia, lung cancer, and other lung diseases. The tests use RNA sequencing and imaging to provide accurate diagnoses that help doctors recommend tailored treatment. In addition to these divisions, Veracyte Inc also offers other products and services, such as information campaigns and training for healthcare professionals, as well as support and counseling for patients and their families. Overall, Veracyte Inc aims to revolutionize the medical field and provide patients with better diagnosis and treatment options. The company's tests offer doctors and patients a more precise and personalized diagnosis, allowing for individualized treatment and achieving the best results. Veracyte is one of the most popular companies on Eulerpool.com.

Veracyte Revenue by Segment

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Veracyte Revenue by Segment

Segmente20232022202120202019
Testing revenue326.54 M USD250.54 M USD1.5 M USD--
Biopharmaceutical and other revenue18.92 M USD33.36 M USD19.87 M USD--
Product revenue15.59 M USD12.63 M USD11.46 M USD-923,000 USD
Testing revenue----107.36 M USD
Testing---101.97 M USD-
Product---9.85 M USD-
Biopharmaceutical revenue----8.09 M USD
Other Testing Revenue7.8 M USD----
Biopharmaceutical---5.67 M USD-
Collaboration revenue----4 M USD
Collaboration-----
Biopharmaceutical revenue-26.34 M USD---
Development services--10.39 M USD--
Contract manufacturing and testing-7.02 M USD---
Collaboration milestones--4 M USD--
Contract manufacturing--2.87 M USD--
Provision of data--1.88 M USD--
Contract testing--383,000 USD--
Milestones--350,000 USD--
Development rights-----

Veracyte Revenue by Region

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Veracyte Revenue by Segment

DateInternationalUnited States
202326.53 M USD334.53 M USD
202233.61 M USD262.92 M USD
202118.53 M USD200.98 M USD
20207.87 M USD109.61 M USD

Veracyte SWOT Analysis

Strengths

Veracyte Inc has a strong and experienced leadership team, which enables effective decision-making and strategic planning.

The company has developed innovative and highly accurate genomic diagnostic tests that provide valuable insights for physicians and patients.

Veracyte has established partnerships with key healthcare providers, allowing for broader market reach and increased adoption of its products.

Weaknesses

Veracyte's success heavily relies on the acceptance and adoption of genomic testing technology within the medical community.

The company faces potential challenges in terms of regulatory compliance and obtaining necessary approvals for its diagnostic tests.

Veracyte may experience increased competition in the future as new players enter the genomic diagnostic testing market.

Opportunities

The growing focus on personalized medicine and precision healthcare presents significant opportunities for Veracyte to expand its customer base and market share.

The increasing prevalence of diseases such as cancer and lung disorders provides a substantial opportunity for Veracyte to further develop and market its diagnostic tests.

Veracyte can leverage advancements in technology and data analysis to enhance the accuracy and efficiency of its genomic testing platform.

Threats

Changes in healthcare policies and reimbursement regulations could impact the pricing and accessibility of Veracyte's diagnostic tests.

Veracyte may face legal and ethical challenges regarding the collection, storage, and use of genetic data for diagnostic purposes.

The emergence of alternative diagnostic technologies and approaches poses a threat to Veracyte's market position.

Veracyte Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Veracyte historical P/E ratio, EBIT multiple, and P/S ratio

Veracyte shares outstanding

The number of shares was Veracyte in 2023 — This indicates how many shares 72.644 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Veracyte earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Veracyte's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Veracyte’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Veracyte's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Veracyte.

Veracyte latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.02 0.07  (521.69 %)2024 Q2
3/31/2024-0.16 -0.02  (87.65 %)2024 Q1
12/31/2023-0.1 -0.39  (-309.66 %)2023 Q4
9/30/2023-0.15 -0.41  (-174.06 %)2023 Q3
6/30/2023-0.16 -0.12  (22.98 %)2023 Q2
3/31/2023-0.14 -0.11  (19.35 %)2023 Q1
12/31/2022-0.15 -0.05  (67.64 %)2022 Q4
9/30/2022-0.25 -0.12  (52.66 %)2022 Q3
6/30/2022-0.22 -0.13  (41.68 %)2022 Q2
3/31/2022-0.24 -0.2  (17.53 %)2022 Q1
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the Veracyte stock

Eulerpool World ESG Rating (EESG©)

78/ 100

🌱 Environment

84

👫 Social

99

🏛️ Governance

50

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees59
Percentage of women in management—
Percentage of Asian employees32
Share of Asian management—
Percentage of Hispanic/Latino employees10
Hispano/Latino Management share—
Percentage of Black employees5
Black Management Share—
Percentage of white employees50
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Veracyte shareholders

%
Name
Stocks
Change
Date
9.24887 % The Vanguard Group, Inc.7,104,05652,69912/31/2023
9.20249 % Wellington Management Company, LLP7,068,43557112/31/2023
9.16910 % ARK Investment Management LLC7,042,783-612,8203/31/2024
7.62270 % BlackRock Institutional Trust Company, N.A.5,854,993362,98312/31/2023
4.39097 % Dimensional Fund Advisors, L.P.3,372,703161,07312/31/2023
4.35807 % Nikko Asset Management Co., Ltd.3,347,436242,7603/31/2024
4.18920 % Artisan Partners Limited Partnership3,217,728-193,39412/31/2023
4.04718 % State Street Global Advisors (US)3,108,639-142,65312/31/2023
3.27710 % ArrowMark Colorado Holdings, LLC2,517,140206,28112/31/2023
2.84893 % Champlain Investment Partners, LLC2,188,260-115,94012/31/2023
1
2
3
4
5
...
10

Veracyte Executives and Management Board

Mr. Marc Stapley53
Veracyte Chief Executive Officer, Director (since 2021)
Compensation 4.94 M
Ms. Rebecca Chambers45
Veracyte Chief Financial Officer
Compensation 3.32 M
Ms. Annie Mcguire43
Veracyte Chief People Officer, Executive Vice President
Compensation 2.45 M
Dr. Eliav Barr58
Veracyte Independent Director
Compensation 518,746
Mr. Jens Holstein59
Veracyte Independent Director
Compensation 318,370
1
2
3

Veracyte Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
NanoString Technologies Stock
NanoString Technologies
SupplierCustomer0,810,840,840,840,710,83
Johnson & Johnson Stock
Johnson & Johnson
SupplierCustomer0,51-0,07-0,38-0,58-0,49-0,04
UnitedHealth Group Stock
UnitedHealth Group
SupplierCustomer0,360,70-0,25-0,51-0,64-0,28
AstraZeneca Stock
AstraZeneca
SupplierCustomer-0,490,26-0,54-0,63-0,51-0,66
CareDx Stock
CareDx
SupplierCustomer-0,570,580,720,780,530,68
1

Most common questions regarding Veracyte

What values and corporate philosophy does Veracyte represent?

Veracyte Inc represents values of innovation, collaboration, and patient-centricity. With a strong corporate philosophy focused on improving patient outcomes, the company combines cutting-edge genomic diagnostic solutions with machine learning to deliver accurate and actionable results. Veracyte Inc is committed to empowering physicians with reliable and timely information, helping them make informed decisions about patient care. The company's dedication to research and development ensures the continuous improvement of its products, leading to better diagnostic accuracy and personalized treatment options. Through its commitment to excellence and patient advocacy, Veracyte Inc is transforming the field of diagnostics and improving healthcare outcomes.

In which countries and regions is Veracyte primarily present?

Veracyte Inc primarily operates in the United States.

What significant milestones has the company Veracyte achieved?

Veracyte Inc has achieved significant milestones since its establishment. Notably, the company successfully launched the Afirma Genomic Sequencing Classifier, a groundbreaking diagnostic test used to detect thyroid cancer with high accuracy. Veracyte also received approval from the U.S. Food and Drug Administration (FDA) for its Percepta Bronchial Genomic Classifier, a test aiding in the diagnosis of lung cancer. Furthermore, the company expanded its product portfolio by introducing the Envisia Genomic Classifier, utilized for diagnosing idiopathic pulmonary fibrosis (IPF). Veracyte's commitment to innovative genomics and precision medicine has positioned itself as an industry leader, revolutionizing molecular diagnostic solutions for improved patient care.

What is the history and background of the company Veracyte?

Veracyte Inc. is a renowned molecular diagnostics company with a rich history and background. Founded in 2008, Veracyte has been dedicated to improving patient outcomes by providing genomic testing solutions. Based in South San Francisco, California, the company combines advanced genomic technology with machine learning to deliver accurate and reliable diagnostic information to physicians and patients. Veracyte's innovative products, such as the Afirma Genomic Sequencing Classifier and Percepta Bronchial Genomic Classifier, have revolutionized the diagnosis of thyroid and lung cancers. Veracyte Inc. has grown rapidly over the years and continues to make significant contributions to the field of molecular diagnostics, benefiting countless patients and healthcare professionals alike.

Who are the main competitors of Veracyte in the market?

The main competitors of Veracyte Inc in the market are companies like Genomic Health Inc, Myriad Genetics Inc, and NanoString Technologies Inc.

In which industries is Veracyte primarily active?

Veracyte Inc is primarily active in the industry of molecular diagnostics.

What is the business model of Veracyte?

The business model of Veracyte Inc is focused on providing genomic diagnostic tests to healthcare providers. Veracyte Inc utilizes advanced genomic technology to analyze patient samples and provide accurate diagnoses for various diseases, including cancer. By offering non-invasive and reliable diagnostic solutions, Veracyte Inc aims to improve patient care and outcomes. With its innovative and comprehensive testing portfolio, the company collaborates with physicians, researchers, and biopharmaceutical companies to enhance the understanding and treatment of complex diseases. As a leading genomic diagnostics company, Veracyte Inc is dedicated to transforming patient care through its precision medicine approach and cutting-edge technology.

What is the P/E ratio of Veracyte 2024?

The Veracyte P/E ratio is 253.94.

What is the P/S ratio of Veracyte 2024?

The Veracyte P/S ratio is 5.56.

What is the AlleAktien quality score of Veracyte?

The AlleAktien quality score for Veracyte is 4/10.

What is the revenue of Veracyte 2024?

The expected Veracyte revenue is 444.73 M USD.

How high is the profit of Veracyte 2024?

The expected Veracyte profit is 9.74 M USD.

What is the business model of Veracyte

Veracyte Inc. is an emerging company specializing in the development of innovative diagnostic tests for cancer. The company's business model relies on a combination of technological innovation, close collaboration with medical professionals, and a strong distribution strategy. The products of Veracyte Inc. are designed to enable better diagnosis and therapy for cancer, thereby increasing the chances of cure. The company focuses on three main areas: endocrinology, lung cancer, and mesothelioma. Within endocrinology, Veracyte Inc. offers an innovative diagnostic procedure for thyroid nodules called the "Afirma Test," which allows for accurate differentiation between benign and malignant nodules without the need for surgery. This enables doctors to recommend targeted, non-invasive therapy and avoid unnecessary operations. In the field of lung cancer, the company has developed the "Percepta" test, which enables non-invasive diagnosis of lung cancer. The test uses RNA sequencing and analysis of protein content in lung fluid to make an accurate diagnosis of cancer cells. This allows for early diagnosis of lung cancer, increasing the chances of cure and avoiding unnecessary investigations and operations. The third area, mesothelioma, focuses on a rare form of cancer caused by asbestos exposure. Here, Veracyte Inc. offers the "Envisia" test, which enables accurate diagnosis of mesothelioma. The test uses specific markers and RNA sequencing to make an accurate diagnosis. Veracyte Inc. works closely with medical professionals and clinics to increase the acceptance and dissemination of its products. The company relies on a targeted distribution strategy and a strong online presence. By implementing targeted marketing and training for healthcare professionals and creating awareness among patients, the aim is to achieve broad acceptance of the products. In summary, the business model of Veracyte Inc. is based on the development of innovative diagnostic tests for various types of cancer. By collaborating closely with medical professionals and implementing a targeted distribution strategy, the company aims to increase the acceptance and dissemination of its products. The company is committed to increasing the chances of cure for cancer patients and avoiding unnecessary investigations and operations.

What is the Veracyte dividend?

Veracyte pays a dividend of 0 USD distributed over payouts per year.

How often does Veracyte pay dividends?

The dividend cannot currently be calculated for Veracyte or the company does not pay out a dividend.

What is the Veracyte ISIN?

The ISIN of Veracyte is US92337F1075.

What is the Veracyte WKN?

The WKN of Veracyte is A1W7EA.

What is the Veracyte ticker?

The ticker of Veracyte is VCYT.

How much dividend does Veracyte pay?

Over the past 12 months, Veracyte paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Veracyte is expected to pay a dividend of 0 USD.

What is the dividend yield of Veracyte?

The current dividend yield of Veracyte is .

When does Veracyte pay dividends?

Veracyte pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Veracyte?

Veracyte paid dividends every year for the past 0 years.

What is the dividend of Veracyte?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Veracyte located?

Veracyte is assigned to the 'Health' sector.

Wann musste ich die Aktien von Veracyte kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Veracyte from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did Veracyte pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of Veracyte in the year 2023?

In the year 2023, Veracyte distributed 0 USD as dividends.

In which currency does Veracyte pay out the dividend?

The dividends of Veracyte are distributed in USD.

All fundamentals about Veracyte

Our stock analysis for Veracyte Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Veracyte Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.